Donald Trump decrees priority for U.S. access to vaccines

Donald Trump is trying to impose his doctrine of “America First” on the vaccine against COVID-19. He has signed a decree in which he demands a priority access of the United States to all the vaccines developed in the country or with federal funds.

This occurs when The United States is one step away from approving the vaccine from Pfizer / BioNTech, which could receive approval from the FDA this weekend, starting an immediate vaccination of the population. Urge, because the US has already exceeded the 286,000 dead and more than fifteen million positive cases of COVID-19.

Biden presents a plan against the pandemic for his first 100 days in office

In this context, Joe Biden has presented a plan against the pandemic for his first 100 days in office, in which he promises to put 100 million vaccines, reopen schools and impose the use of the mask, which will be mandatory in all federal administrations, as well as in interstate transportation.

“My first 100 days will not kill the virus. That is something I cannot promise. Biden said. It’s going to take some time, but I am absolutely convinced that in 100 days we can change the course of the disease and change the lives of Americans for the better. “

Trump tries to tie the vaccine to his legacy

Donald Trump tries to tie the vaccine to his legacy and take credit for its rapid development, stressing that it has been thanks to the fact that his Government has made an “unprecedented investment.”

“We are just days away from FDA clearance and we are pushing them hard. When it arrives, we will immediately begin mass distribution. Before ‘Operation Warp Speed,’ the time for development and approval of a vaccine could be infinite. We are very happy to have been able to do things at a level that no one has seen before. “he said during a summit at the White House focused on the pandemic.

Since you have put a lot of money, Trump considers that the United States should be supplied as a priority by the pharmaceutical companies that have developed their vaccine in the country, such as Pfizer, or that have received federal funds, which is the case of Moderna and AstraZeneca.

His wish has been embodied in a decree that, however, does not seem to have a long way to go, since he only has six weeks in office. This time seems insufficient for it to prevent pharmaceutical companies from fulfilling their contracts with other countries that, in many cases, have also contributed funds to the development of vaccines.